Following the spin-off of Bluebird’s oncology programs into 2Seventy bio, Bluebird CEO Andrew Obenshain addresses his company’s focus on severe genetic disease and his steadfast belief in lentiviral vectors
Bluebird Bio CEO Andrew Obenshain says the company is now in a much better position to address its multiple challenges—especially investor concerns about execution—by bringing to market three gene therapies for severe genetic diseases over the next two years, while containing costs. [Bluebird Bio]
Bluebird Bio completed the spinoff of its cancer business earlier this month, leaving the company with Obenshain, who was previously president of the company’s genetic diseases business, at the helm—as well as three late-stage gene therapy candidates for severe genetic diseases; a partnered Phase I short hairpin RNA (shRNA)-based treatment targeting BCL11A mRNA for sickle-cell disease (SCD); and “multiple” undisclosed preclinical candidates . . .
